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Abstract 
Background: Pregnancy has been reported to alter the pharmacokinetic properties of anti-malarial drugs, includ-
ing the different components of artemisinin-based combination therapy (ACT). However, small sample sizes make it 
difficult to draw strong conclusions based on individual pharmacokinetic studies. The aim of this review is to sum-
marize the evidence of the influence of pregnancy on the pharmacokinetic properties of different artemisinin-based 
combinations.
Methods: A PROSPERO-registered systematic review to identify clinical trials that investigated the influence of 
pregnancy on the pharmacokinetic properties of different forms of ACT was conducted, following PRISMA guide-
lines. Without language restrictions, Medline/PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of 
Science, LILACS, Biosis Previews and the African Index Medicus were searched for studies published up to November 
2015. The following components of ACT that are currently recommend by the World Health Organization as first-line 
treatment of malaria in pregnancy were reviewed: artemisinin, artesunate, dihydroartemisinin, lumefantrine, amodi-
aquine, mefloquine, sulfadoxine, pyrimethamine, piperaquine, atovaquone and proguanil.
Results: The literature search identified 121 reports, 27 original studies were included. 829 pregnant women were 
included in the analysis. Comparison of the available studies showed lower maximum concentrations (Cmax) and 
exposure (AUC) of dihydroartemisinin, the active metabolite of all artemisinin derivatives, after oral administration of 
artemether, artesunate and dihydroartemisinin in pregnant women. Low day 7 concentrations were commonly seen 
in lumefantrine studies, indicating a low exposure and possibly reduced efficacy. The influence of pregnancy on amo-
diaquine and piperaquine seemed not to be clinically relevant. Sulfadoxine plasma concentration was significantly 
reduced and clearance rates were higher in pregnancy, while pyrimethamine and mefloquine need more research as 
no general conclusion can be drawn based on the available evidence. For atovaquone, the available data showed a 
lower maximum concentration and exposure. Finally, the maximum concentration of cycloguanil, the active metabo-
lite of proguanil, was significantly lower, possibly compromising the efficacy.
Conclusion: These findings suggest that reassessment of the dose of the artemisinin derivate and some compo-
nents of ACT are necessary to ensure the highest possible efficacy of malaria treatment in pregnant women. However, 
for most components of ACT, data were insufficient and extensive research with larger sample sizes will be necessary 
to identify the exact influences of pregnancy on the pharmacokinetic properties of different artemisinin-based com-
binations. In addition, different clinical studies used diverse study designs with various reported relevant outcomes. 
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(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Background
Malaria infection during pregnancy remains an impor-
tant public health problem with potential life-threatening 
risks for the pregnant woman, the foetus and the newborn 
child [1, 2]. According to a systematic review to assess the 
burden of malaria in pregnancy, approximately 25 million 
pregnant women are at risk of Plasmodium falciparum 
infection every year [3]. One in four women have evidence 
of placental infection at the time of delivery; of which a 
small fraction is encountered as an imported condition 
in non-endemic countries in migrants and travellers [4]. 
Imported cases of malaria in pregnancy are mainly P. 
falciparum acquired in sub-Saharan Africa [4]. Malaria 
in pregnancy is caused by all five species of Plasmodium 
infecting humans: P. falciparum, P. vivax, P. ovale, P. 
malariae and P. knowlesi. Most morbidity and mortality 
is caused by falciparum and vivax malaria. Plasmodium 
knowlesi malaria is endemic in parts of South East Asia 
and is relatively rare in pregnancy.
Pregnancy increases the risk of both falciparum and 
vivax malaria [3, 5]. The increased susceptibility has 
been attributed to broad hormonal and immunological 
changes that occur during pregnancy [5]. For P. falcipa-
rum, there is evidence that the increased susceptibility is 
due to the lack of immunity to antigens expressed only 
by parasites infecting pregnant women [5, 6]. It is unclear 
what causes the increased susceptibility for P. vivax 
malaria in pregnancy [5]. The prevalence of both falcipa-
rum and vivax malaria is higher in primigravidae than in 
non-pregnant women or multigravidae. As well, younger 
age is associated with higher risk for malaria in preg-
nancy [3, 5]. Plasmodium falciparum and P. vivax malaria 
are associated with maternal anaemia, lower birth weight 
and, in low-transmission areas, increased risks of spon-
taneous abortion, severe malaria and stillbirth [3, 7–10]. 
The increased burden of malaria in pregnancy has been 
attributed to higher parasite densities and the seques-
tration of P. falciparum infected erythrocytes (Pf-IEs) 
in the placenta [3, 5, 6, 11–13], resulting in placental 
changes including inflammation and disposition of pig-
ment in fibrin or inflammatory cells, syncytial knotting 
and thickening of the trophoblastic basement membrane 
[5]. Plasmodium vivax however, does not cytoadhere in 
the placenta, but is associated with maternal anaemia and 
low birth weight [3].
In order to reduce the burden of malaria in pregnancy, 
the WHO recommends a three-pronged approach. 
Women are recommended to sleep under long-lasting 
insecticide-impregnated nets (LLINs) and to use inter-
mittent preventive treatment (IPTp) with sulfadoxine-
pyrimethamine (SP) when living in areas with a high to 
moderate stable transmission. The WHO emphasizes 
the importance of prompt diagnosis and effective case 
management of malaria infections [14]. Furthermore, all 
pregnant women should receive iron and folic acid sup-
plementation as a part of routine antenatal care.
In the “Guidelines for the treatment of malaria” (Third 
edition, 2015), the WHO recommends [15] the use of an 
artemisinin-based combination therapy (ACT) for the 
treatment of uncomplicated falciparum malaria in the 
2nd and 3rd trimester of pregnancy [16]. Over the past 
two decades multiple studies have been conducted to 
assess the efficacy and safety of ACT in the 2nd and 3rd 
trimester of pregnancy compared to other treatments 
[17–25]. However, pregnancy is known to cause physi-
ologic and pharmacokinetic changes that might influence 
the efficacy of drugs. Different organ systems undergo 
changes which result in pharmacokinetic changes [26]. 
Pregnancy is associated with significant cardiovascular 
changes, especially in the first trimester of pregnancy. 
Cardiac output, stroke volume and heart rate increase, 
systemic and pulmonary vascular resistance decrease, as 
well as colloid osmotic pressure and haemoglobin con-
centration. This can increase the volume of distribution 
of hydrophilic substrates. Clinically, pregnant women 
sometimes need higher initial and subsequent dosage 
regimens, especially for hydrophilic drugs. In contrast, 
drugs that are bound to proteins or albumin can double 
the fraction of active pharmaceutical fraction. Respira-
tory changes in pregnancy include increased pulmonary 
vascularity, tidal volumes, minute volumes. In later stages 
of pregnancy, lung capacity may decrease because of 
the pressure from a big uterus on the diaphragm, caus-
ing alveolar collapse and atelectasis. In addition, pH of 
maternal blood may be increased, resulting in lower 
serum bicarbonate concentration and a lower buffering 
capacity. Furthermore, a rightward shift of the oxy-hae-
moglobin dissociation curve may affect protein binding 
of some drugs. Also the renal system is altered by preg-
nancy. In the first halve of pregnancy, the renal blood 
Future pharmacokinetic studies could benefit from more uniform designs, in order to increase quality, robustness and 
effectiveness.
Study registration: CRD42015023756 (PROSPERO)
Keywords: Artemisinin combination therapy, ACT, Pregnancy, Pharmacokinetics, Plasmodium falciparum, P. vivax,  
P. ovale, P. malariae, P. knowlesi
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flow and GFR (glomerular filtration rate) is increased. 
Elimination rates can be higher for renal cleared drugs 
resulting in shorter half-lives. The bioavailability (e.g. 
Cmax, T1/2, Tmax) of oral anti-malarial drugs can also 
be changed by gastro-intestinal changes during preg-
nancy. There is delayed gastric emptying, and a longer 
small-bowel transit duration. These factors mainly influ-
ence single dose malaria treatments. Nausea and vom-
iting, common in early pregnancy, can also change the 
bioavailability of the anti-malarial drug caused by lower 
plasma concentrations. Also (sex) hormones during 
pregnancy increase or decrease the plasma concentra-
tions of anti-malarial drugs. In the liver for example, 
CYP3A4 and cytochrome P450 are upregulated, resulting 
in a changed metabolism of CYP3A4 metabolized drugs 
(e.g. lumefantrine). Many other mechanisms have been 
described, however, the most important changes include 
increased maternal fat and total body water, decreased 
plasma protein concentrations, increased maternal blood 
volume and cardiac output and altered activity of hepatic 
drug-metabolizing enzymes [26].
Multiple studies have been conducted to study the 
influence of pregnancy on pharmacokinetic properties of 
ACT. However, due to small sample sizes it is often hard 
to draw strong conclusions based on these individual 
studies [27, 28].
Objectives
The overall objective of this review was to summarize 
available evidence of the influence of pregnancy on the 
pharmacokinetic properties of different artemisinin-
based combinations and the consequences these influ-
ences have on treatment dose and regime. The last review 
on this subject was published in 2009 [29]. The primary 
outcomes of interest for the analysis of the pharmacoki-
netics of the drugs in pregnancy were Cmax, Tmax, CL/F, 
V/F, t1/2 and total exposure (Area Under the Curve: 
AUC).
Methods
This review was conducted in June 2015. The last search 
was conducted on 10 November 2015. Objectives and 
inclusion criteria were specified in advance and docu-
mented in a protocol. Recommendations made by the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) group were followed [30]. This 
review was registered in advance in PROSPERO (Inter-
national prospective register of systematic reviews). Reg-
istration number: CRD42015023756. The full methods 
section and search strategy are described in Additional 
file 1. An overview of ongoing or future trials is provided 
in Additional file 2. The costs of this literature study are 
not reported [31].
Results
The initial search yielded 121 records (Fig.  1: PRISMA 
flow diagram of study selection). 27 articles met the 
inclusion criteria and were included in the analysis 
(Table 1) [18, 19, 32–56]. The main study findings of the 
included trials can be found in Table 2.
The studies included were published between 1990 
and 2015 and included a total of 829 pregnant and 377 
non-pregnant patients. Articles were categorized by the 
drug that was evaluated. If more than one anti-malarial 
was administered, the study was included in both cat-
egories. In total, 34 patients received artemether (34 
pregnant; 0 non-pregnant), 182 artesunate (AS) (94 
pregnant; 88 non-pregnant), 48 DHA (56 pregnant, 57 
non-pregnant), 341 lumefantrine (324 pregnant; 17 non-
pregnant), 46 amodiaquine (27 pregnant, 19 non-preg-
nant), 85 mefloquine (53 pregnant; 32 non-pregnant), 
279 SP (161 pregnant; 118 non-pregnant), 72 PPQ (68 
pregnant; 69 non-pregnant) and 163 AP (105 pregnant, 
58 non-pregnant).
Records identified through 
database searching
(n = 120)
Additional records identified 
through other sources
(n = 1)




Records excluded for not 


















• Proguanil n=2 
Studies included in the systematic 
review
(n = 27)
Fig. 1 PRISMA flow diagram of study selection















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Page 27 of 36Burger et al. Malar J  (2016) 15:99 
Quality assessment of the included studies
Details of the quality assessment are depicted in the table 
in Additional file  3. In summary, studies were given a 
median 23 points (range 16–29) out of 31. Most of the 
studies did not report how patients were selected and did 
not report the percentage of patients who agreed to par-
ticipate. This could compromise the representativeness of 
the study population. There was no blinding of patients, 
researchers or statistical analysis. Overall, the quality of 
the included studies could be evaluated as moderate to 
good.
Studies assessing the pharmacokinetics of ACT
The data sheet (excel file) of the included studies is pro-
vided as Additional file 4.
Artemether and dihydroartemisinin
Two studies investigated the pharmacokinetic properties 
of artemether in pregnant women, following oral adminis-
tration of artemether-lumefantrine (AL) (80/480 mg b.i.d. 
for 3 days) [36, 49]. Tarning et al. [36] studied 21 pregnant 
women in the second or third trimester of pregnancy with 
uncomplicated falciparum malaria. Both a compartmen-
tal (zero-order absorption followed by transit compart-
ment absorption and a simultaneous one-compartment 
drug-metabolite model) and a noncompartmental analy-
sis were performed. The first revealed no statistically sig-
nificant covariates, indicating among others no difference 
between second and third trimester. Results obtained by 
noncompartmental analysis were used to compare the 
pharmacokinetic properties of pregnant women with the 
literature. Estimated exposure to artemether and its active 
metabolite DHA was similar to that reported in pregnant 
Thai patients [49] but lower than that reported in two 
studies in adult non-pregnant patients from Thailand [57, 
58]. However, these results should be interpreted with 
caution since ethnicity might have an impact on the phar-
macokinetic properties of these drugs.
McGready et  al. [49] studied 13 women in the sec-
ond and third trimester of pregnancy with recrudes-
cent uncomplicated multi-drug resistant falciparum 
malaria after 7-day quinine treatment. A noncompart-
mental analysis revealed no significant differences in the 
pharmacokinetic parameters of artemether and DHA 
between the second and third trimester. Comparison 
with data from the literature showed a lower exposure 
(AUC) and maximum concentration (Cmax) of artemether 
compared to male Thai patients and of DHA compared 
to non-pregnant patients [57].
Artesunate and dihydroartemisinin
Six studies investigated the pharmacokinetics after 
administration of AS [33, 41, 46, 47, 51, 59]. Three 
studies described the pharmacokinetic properties of AS 
as well as the pharmacokinetic properties of DHA, the 
active metabolite of AS, that is the principle source of 
anti-malarial activity after AS administration [33, 51]. 
McGready et  al. [51] compared the pharmacokinetics 
of intravenous and oral AS in 20 women with malaria 
during pregnancy and 3  months post-partum without 
malaria. They found no significant differences in AS or 
DHA pharmacokinetics after intravenous administration. 
After oral administration, the exposure of AS and DHA 
(AUC) was significantly higher in pregnant women with 
malaria than in post-partum women without malaria. 
This can be explained by a higher bioavailability and 
lower oral clearance. The authors ascribed the differences 
to a disease related reduction in pre-systemic metabo-
lism, as an active malaria infection tends to increase oral 
bioavailability, and not to the pregnancy. This assumption 
was supported by a decrease in DHA exposure at day 6 
compared with day 0 and 1 in women with malaria but 
not in healthy women.
Kloprogge et al. [59] used the same data as McGready 
et  al. but used a noncompartmental analysis to dissect 
and quantify the individual contributions of malaria and 
pregnancy to the altered pharmacokinetics. They found 
no effect of both malaria and pregnancy on pharma-
cokinetic properties of intravenous AS and DHA. How-
ever, their research showed opposite and independent 
effects for malaria (87 % increase) and pregnancy (23 % 
decrease) on the absolute oral bioavailability of artesu-
nate. Both findings are in line with conclusions drawn 
by McGready et al. and ask for further dose optimization 
studies.
Valea et  al. [33] studied the pharmacokinetics of AS 
and DHA in 24 pregnant women and 24 controls. They 
found a significantly lower oral clearance (CL/F) and 
higher exposure (AUC) of AS in pregnant women com-
pared to the non-pregnant women. However, they did 
not find significant differences for DHA. It is important 
to notice that there was a significantly higher parasite 
density in the pregnant women’ group, possibly resulting 
in higher exposure, which might have masked the preg-
nancy-related effects.
Three other studies reported only the pharmacoki-
netic properties of DHA [41, 46, 47]. Onyamboko et  al. 
[41] compared 26 pregnant women with malaria with 
the same women three months post-partum and with 
25 non-pregnant parasitaemic controls. After a single 
dose of orally administred AS, there appeared to be no 
significant and clinically relevant differences in DHA 
pharmacokinetics between the women in pregnant 
and post-partum state. However, the exposure of DHA 
(AUCfree) was significantly lower in pregnant women 
compared to non-pregnant controls (the authors used 
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a 90  % confidence interval), which is consistent with a 
significantly increased clearance (CL/F) in the pregnant 
group. The authors described a couple of reasons for 
this apparent difference between pregnant women and 
non-pregnant controls and the absence of this differ-
ence between pregnant and post-partum women, namely 
that the physiological changes that occur during preg-
nancy might remain 3  months post-partum, that lacta-
tion influences pharmacokinetics, that most post-partum 
women were not parasitaemic and that a comparison in 
the same women mitigates the effects of potential other 
confounders.
The investigation by Morris et al. [46] is based on the 
same clinical study, but used a compartmental analy-
sis (one compartmental analysis with mixed zero order, 
lagged first-order absorption for AS) instead of a non-
compartmental analysis to describe the data. In the 
final model, pregnancy status was the only covariate 
that had a significant influence on DHA clearance, sug-
gesting a faster clearance of DHA in pregnant women. 
Together with the data from Onyamboko et  al., the 
authors conclude that this provides further evidence 
that higher doses of AS would be required in pregnant 
women. Another study by McGready et  al. [47] from 
2006 (n  =  24) showed lower exposure (AUC) to DHA 
and higher rates of clearance and apparent volume of 
distribution in pregnant women compared to literature 
on non-pregnant women, although this should be inter-
preted with caution as differences in methodology of the 
studies might explain (part of ) the differences [60].
Dihydroartemisinin
Three articles report the pharmacokinetic properties 
of oral DHA [34, 39, 56]. Rijken et al. and Tarning et al. 
papers are based on one study into the pharmacokinet-
ics of DHA after the oral administration of DHA-PQ (6.4 
and 51.2 mg/kg p.o. q.d. for 3 days) [34, 39]. Rijken et al. 
[39] used a noncompartmental analysis to describe the 
pharmacokinetic properties in 24 pregnant women and 
24 controls with acute falciparum malaria. They report 
no significant differences in total DHA exposure or maxi-
mum concentration between the two groups, although 
the DHA exposure after the first dose was significantly 
lower among the pregnant women, and there was seem-
ingly a trend of lower exposure after the other doses. 
As well, there was a trend towards higher clearance in 
pregnant women, but this did not reach statistical sig-
nificance. However, the authors warn for the potentially 
masking effect of the high inter-individual variability.
Using a mono-compartmental disposition model, Tarn-
ing et al. [34] report a 38 % lower total exposure to DHA 
in pregnant women compared to the controls (p = 0.001), 
consistent with a significantly higher apparent volume of 
distribution (p =  0.008) and clearance rate (p =  0.001). 
This could be explained by pregnancy related induc-
tion of hepatic glucuronidation enzymes resulting in 
an increased first-pass metabolism and accelerated 
clearance.
Benjamin et  al. [56] report no differences in pharma-
cokinetic properties of DHA between pregnant and non-
pregnant women without malaria after oral DHA-PQ (7 
and 58 mg/kg q.d. for 3 days).
Lumefantrine
The pharmacokinetic properties of lumefantrine were 
investigated in six studies [18, 19, 35, 37, 49, 61]. A study 
by McGready et  al. [49] in 13 pregnant women with 
recrudescent falciparum malaria showed significantly 
lower lumefantrine AUC values in pregnant women 
than in non-pregnant patients from studies with uncom-
plicated malaria, caused by more rapid lumefantrine 
elimination in pregnant women. The large proportion 
of smokers among the non-pregnant patients made it 
difficult to draw strong conclusions on the cause of this 
difference. Also, they reported a proportion of 38  % of 
pregnant women with a day 7 lumefantrine concentra-
tion below 280 ng/ml, which is associated with high fail-
ure rates (49 %) [62].
The study by McGready et  al. from 2006 was nested 
in a larger trial to assess the efficacy, safety, tolerability 
and pregnancy outcomes of AL in pregnant women [18]. 
Apart from these outcomes, the study by McGready et al. 
[18] from 2008 describes day 7 capillary plasma lume-
fantrine concentrations in 85 patients. In total, 35  % 
of patients had a day 7 capillary plasma concentration 
below 355 ng/ml (which corresponds with 280 ng/ml in 
venous plasma). All 21 (100 %) patients with levels over 
600  ng/ml were cured, while patients with lower values 
had recrudescent infections (p < 0.001).
A third study nested in the trial mentioned above 
investigated the population pharmacokinetics of lume-
fantrine in 103 pregnant women with uncomplicated 
multidrug-resistant falciparum malaria [35]. Using a 
two-compartment model with first-order absorption and 
elimination, they predicted a 12 % odds increase in recru-
descence and 7.2  % increase in apparent volume of dis-
tribution for each successive week of EGA on admission 
for pregnant women. Also, they showed a non-significant 
trend (p = 0.26) for the predicted day 7 median capillary 
lumefantrine concentrations to be lower in women with 
a recrudescent [n =  17; median concentration: 388  ng/
ml (range 126–536)] or new infection [n =  21; median 
concentration: 377 ng/ml (range 136–1210)] compared to 
women who had no recrudescence [n = 65, median con-
centration: 427 ng/ml (range 135–1600)]. Based on differ-
ent dose regime simulations using their final model, they 
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recommend a 5-day regime instead of a 3-day regime to 
increase exposure to artemether and DHA and increase 
day 7 plasma lumefantrine concentration.
The study by Piola et al. [19] reports the data of a large 
efficacy study conducted in 304 pregnant women with 
uncomplicated falciparum malaria, of whom 152 received 
quinine en 152 received AL. For 97 of the women who 
received AL, the day 7 plasma lumefantrine concentra-
tion was available. 32  % of women had a lumefantrine 
concentration below 280  ng/ml (venous plasma). Also 
the reappearance of malaria was significantly associated 
with decreased plasma concentrations of lumefantrine 
[Reappearance: 422  ng/ml (range 15–3246) vs no reap-
pearance: 240 ng/ml (range 123–454); p = 0.01].
Nested into this efficacy trial was a pharmacokinetic 
study, which compared pharmacokinetics of lumefan-
trine in pregnant (n  =  26) and non-pregnant (n  =  17) 
women [37]. This study by Tarning et al. showed no sta-
tistical difference in total lumefantrine exposure, appar-
ent volume of distribution of elimination clearance 
between the two groups. Tmax and T1/2 were significantly 
shorter in pregnant women. The day 7 concentration of 
lumefantrine was lower among pregnant women (488 ng/
ml [range 30.7–3550] in pregnant women vs 720 [range 
339–2150] in non-pregnant women), but this difference 
was not statistically significant (p =  0.128). Fifteen per-
cent of the pregnant women had a day 7 lumefantrine 
venous plasma concentration below 280  ng/ml, while 
none of the women in the non-pregnant control group 
had day 7 lumefantrine venous plasma concentrations 
below 280 ng/ml. With this in view, the study suggested 
no significant correlation between week of EGA and drug 
exposure.
A third study, nested in the efficacy trial, was per-
formed by Kloprogge et al. [61]. The same data as Tarn-
ing et  al. was used, plus day 7 capillary lumefantrine 
concentrations of 89 pregnant women with P. falcipa-
rum malaria. Based on a transit-compartment absorp-
tion model followed by a two-compartment disposition 
mode, a 27 % lower day 7 lumefantrine concentration in 
pregnant women was found compared to non-pregnant 
women., caused by a 36.5  % decrease in intercompart-
mental clearance during pregnancy. Although this cor-
responded with a previous study in Thailand [49], the 
cure rate was higher in this study, possibly resulting from 
higher background immunity or less lumefantrine resist-
ance in Uganda compared to Thailand.
Amodiaquine
The pharmacokinetics of amodiaquine were investi-
gated in two studies [38, 40]. Rijken et  al. [40] reported 
no difference in pharmacokinetic parameters between 
pregnant women with P. vivax malaria (n  =  24) and 
post-partum women (n =  19), except for the maximum 
concentration (Cmax) of desethylamodiaquine (DEAQ), 
the principle metabolite of amodiaquine, that was sig-
nificantly lower in pregnant women (p  =  0.019). How-
ever, because the difference was below 10  % and the 
total exposure to (desethyl)amodiaquine did not differ 
significantly, the clinical impact of this difference was 
considered limited. There was no significant difference 
in pharmacokinetic parameters between the 2nd and 
3rd trimester of pregnancy. Also, there was no signifi-
cant pharmacokinetic difference between post-partum 
women with P. vivax malaria and those without it, mak-
ing it unlikely that a disease effect masked the differences 
between pregnant and post-partum women. Pregnant 
women with recurrent P. vivax malaria did have a sig-
nificantly lower dose-normalized amodiaquine exposure 
than post-partum women (p  =  0.036), suggesting that 
high drug exposure suppresses recurrent malaria.
Tarning et al. [38] did a compartmental analysis of the 
same data using a lagged first-order absorption with a 
two-compartment disposition model followed by a three-
compartment disposition of desethylamodiaquine. They 
found a relatively small effect of age of amodiaquine 
clearance (1.36  % reduction per year), which might 
be related to an increased immunity in older patients 
and reflect reduced severity of the disease. Also, preg-
nant patients had a reduced absorption lag time (41.6 % 
decrease), possibly as a result of increased cardiac out-
put resulting in an increased blood flow to the stomach 
and small intestine [63]. Neither pregnancy status nor 
estimated gestational age resulted in a clinically relevant 
impact on other pharmacokinetic parameters.
Mefloquine
The pharmacokinetics of mefloquine in pregnancy 
have been investigated initially in the 90 s, and been re-
examined recently [33, 43, 45]. Nosten et al. [43] investi-
gated the pharmacokinetics in 20 pregnant women who 
received either 125 of 250  mg of oral mefloquine mon-
otherapy. They compared their outcomes with the lit-
erature and found a higher oral clearance and a shorter 
terminal elimination half-life in pregnant women. There 
was no evidence of delayed absorption. Mean maximum 
concentrations of mefloquine in women who received 
250  mg of AS were significantly lower than previously 
reported in six healthy Brazilian volunteers [64–76].
Na Bangchang et  al. [45] compared nine pregnant 
women with eight non-pregnant women, all suffering 
from uncomplicated falciparum malaria, who received 
a single-dose treatment of mefloquine (15 mg/kg). They 
found a significantly lower maximum concentration of 
whole blood mefloquine (p  =  0.015) and an increased 
total apparent volume of distribution (p = 0.046) in the 
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pregnant women. The pregnant women also tended to 
have increased times to peak concentration (Tmax) com-
pared to non-pregnant women. However, this difference 
was not statistically significant. Systematic clearance 
and terminal elimination half-life’s were similar in both 
groups. No correlation between EGA and apparent V/F, 
t1/2 of CL/F were seen.
Valea et al. [33] investigated the pharmacokinetic prop-
erties of mefloquine in combination with AS. They com-
pared the pharmacokinetic parameters of 24 pregnant 
and 24 non-pregnant women with uncomplicated falci-
parum malaria, treated with a fixed-dose combination of 
oral mefloquine and AS (8/3.6 mg/kg per day for 3 days). 
They found very similar values for Cmax, Tmax and V/F in 
pregnant and non-pregnant women. However, t1/2 was 
significantly longer in pregnant women than in non-preg-
nant women (390.2 vs 289.2 h; p < 0.001). Also, pregnant 
women tended to have longer clearance time and higher 
exposure to mefloquine, but these differences were not 
statistically significant. The exposure to carboxymeflo-
quine (an inactive metabolite of mefloquine), however, 
was lower in pregnant women, consistent with a higher 
apparent volume of distribution and clearance. These 
findings suggest that the higher exposure to mefloquine 
may be a result of decreased carboxylation of mefloquine, 
although the increase in exposure to mefloquine was not 
completely proportional to the decrease in exposure to 
carboxymefloquine.
Sulfadoxine‑pyrimethamine
Three studies investigated the pharmacokinetic prop-
erties of SP [42, 52, 54]. Green et  al. [54] used a one-
compartmental analysis to compare the outcome of 
33 pregnant (n  =  11: parasitaemic; n  =  22: aparasitae-
mic) and 11 post-partum women without symptomatic 
malaria (n  =  1: parasitaemic; n  =  10: aparasitaemic) 
treated with the standard single dose SP (1500/75  mg). 
Linear regression showed a significant effect of parity sta-
tus on sulfadoxine half-life as well as on exposure (AUC). 
The half-life of sulfadoxine was significantly shorter (148 
vs 256  h; p  <  0.0001); exposure (AUC) was significantly 
lower (22,816 vs 40,106  µg/ml/h; p  <  0.001); and the 
plasma clearance rate was significantly higher (65.9 vs 
36.9  ml/h; p  <  0.001) during pregnancy compared with 
the post-partum period. Pregnancy status showed no sig-
nificant effect on the distribution volume. For pyrimeth-
amine, none of the pharmacokinetic parameters differed 
significantly between the pregnant and post-partum 
women, although the median half-life and exposure 
(AUC) were lower, yet not significantly.
Karunajeewa et al. [52] compared the pharmacokinetic 
properties of SP in 30 pregnant and 30 age-matched non-
pregnant women who received IPTp (SP 1500/75  mg 
once and chloroquine 1350  mg q.d. for 3  days). They 
found a significantly lower exposure (AUC) for sulfadox-
ine (33 %), for N-acetylsulfadoxine (a metabolite of sulf-
adoxine) and for pyrimethamine (32  %) in the pregnant 
group; which is in line with the significantly higher clear-
ance rates for (N-acetyl)sulfadoxine and pyrimethamine 
found in this study. The total apparent volume of distri-
bution was significantly higher in pregnant women for 
(N-acetyl)sulfadoxine and pyrimethamine. The terminal 
elimination rate of sulfadoxine and N-acetylsulfadoxine 
was significantly higher in pregnant women, while the 
terminal elimination rate of pyrimethamine was signifi-
cantly lower in this group.
Nyunt et  al. [42] investigated the pharmacokinet-
ics of SP in Intermittent Preventive Treatment (IPTp) 
of malaria in 98 pregnant and 77 post-partum women 
from four African countries. Using a one-compartment 
model, they found significantly higher maximum con-
centrations of sulfadoxine in pregnant women, but lower 
exposure (AUC), faster clearance, smaller volume of dis-
tribution and shorter elimination half-lifes during preg-
nancy, all statistically significant. Day 7 concentrations 
of sulfadoxine did not differ significantly; however, after 
adjusting for potential covariates, they were significantly 
lower during pregnancy. Day 7 concentrations appeared 
to be lower in the third than in the second trimester, 
but this difference was not statistically significant. For 
pyrimethamine, drug exposure was higher during preg-
nancy, which is consistent with a significantly slower total 
clearance, longer elimination half-life and an apparently 
smaller distribution volume during pregnancy. As well, 
the unadjusted day 7 concentration of pyrimethamine 
was significantly higher in pregnant women. All phar-
macokinetic parameters varied significantly between the 
study sites.
Piperaquine
Five articles report the pharmacokinetic properties of 
PQ. Two studies conducted by Rijken et al. and Tarning 
et al. are based on one study of the pharmacokinetics of 
PQ after the oral administration of DHA-PPQ (6.4 and 
51.2  mg/kg q.d. divided over 3  days) [34, 39]. The find-
ings for DHA are described above. Rijken et al. [39] used 
a non-compartmental analysis to describe the pharma-
cokinetic properties of PPQ in 24 pregnant and 24 non-
pregnant women with falciparum malaria. They found 
no significant difference in total PPQ exposure between 
the pregnant and non-pregnant women. However, the 
exposure in the first 72 h (AUC0-24 h; AUC24-48 h and 
AUC48-72  h) was significantly higher in the pregnant 
women; as well, the day 7 concentration was significantly 
elevated. The apparent volume of distribution was sig-
nificantly smaller (602 vs 877 L/kg; p = 0.0057) and the 
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terminal elimination half-life was significantly shorter 
(17.8 vs 25.6 days; p = 0.0023) in the pregnant group. No 
statistically significant difference was found in clearance 
rate. The Cmax was elevated after each dose, but only sig-
nificantly after the first two doses.
Tarning et  al. [34] did a compartmental analysis with 
the same data, using a three-compartment disposition 
model with a 45  % higher elimination clearance and 
a 47  % increase in relative bioavailability in pregnant 
women compared with non-pregnant women. They 
found no effect of pregnancy on exposure of PPQ. How-
ever, the terminal elimination half-life was shorter (17.5 
vs 24.0 days; p < 0.001), the apparent volume of distribu-
tion lower (529 vs 829 L/kg; p < 0.001) and the maximum 
concentration higher (291 vs 216 ng/ml; p = 0.035) in the 
pregnant women. The time to maximum concentration, 
clearance rate and day 7 and 28 concentration did not dif-
fer significantly between the two groups.
Adam et  al. [55] reported a significantly higher expo-
sure (AUC0-24; 1.8 vs 0.86  µg  h/ml; p  =  0.01) and a 
longer time to maximum concentration (Tmax; 4.00 
vs 1.50; p  =  0.02) after the first dose of DHA-PPQ 
(24/20  mg/kg q.d. for 3  days) in 12 pregnant women 
compared to 12 non-pregnant women with uncompli-
cated falciparum malaria. No other significant differences 
were observed, including no difference in total exposure 
(AUC0-∞). That notwithstanding, there was a trend 
towards higher maximum concentrations of PPQ and a 
shorter half-life in pregnant women, compared to non-
pregnant women.
A compartmental analysis using a three-compartment 
disposition model with a transit-absorption model of the 
same data was performed by Hoglund et  al. [53]. They 
found a significantly higher maximum concentration 
(Cmax; 185 vs 102  ng/ml; p =  0.021) and longer time to 
maximum concentration (Tmax; 30.7 vs 1.48 h; p = 0.018) 
in the 12 pregnant women compared to the 12 non-
pregnant women. The terminal elimination half-life was 
shorter in the pregnant group (t1/2; 22.1 vs 25.7  days; 
p = 0.001). However, no significant differences in expo-
sure to PPQ and day 7 and 28 concentrations were 
observed.
Benjamin et  al. [56] reported a 33  % lower exposure 
(AUC; 23.721 vs 35.644  µg  h/L; p  <  0.001) in pregnant 
women compared to non-pregnant women, consistent 
with a significantly shorter half-life (t1/2; 382 vs 488  h; 
p  <  0.001) and a higher clearance rate (CL/F; 73.5 vs 
53.8 L/h; p < 0.001).
Atovaquone‑proguanil (AP)
The pharmacokinetic properties of proguanil (PG) 
were first studied in 1993 by Wangboonskul et  al. [32]. 
The pharmacokinetic parameters of PG (pro-drug), 
cycloguanil (CG) (active metabolite) and 4-chlorophe-
nylbiguanide (inactive metabolite) were compared in 
10 healthy pregnant women, four post-partum women 
and nine male patients; all treated with PG (200 mg p.o. 
once) [77]. They found a significantly lower maximum 
concentration of CG in pregnant women (Cmax; 12.5 
vs 28.4 (post-partum) and 39.3 (male) ng/ml; p  <  0.05) 
and a significantly shorter terminal elimination half-life 
for PG (t1/2; 12.3 vs 17.1 (post-partum) and 16.1 (male) 
h; p  <  0.01) in the pregnant group. The total exposure 
(AUC) of CG in pregnant women was approximately 
half of the exposure in male and post-partum patients. 
The mean ratio of the exposure of PG to CG was 18.0 in 
pregnancy, compared to 7.8 post-partum. The 4-chloro-
phenylbiguanide maximum concentration was lower in 
the pregnant women than in the post-partum and male 
patients, but not significantly. All these observations 
seemed to indicate an impaired conversion of pro-drug 
to (active) metabolite.
McGready et al. [50] investigated the pharmacokinetic 
properties of AS-AP (4/20/8 mg/kg p.o. q.d. for 3 days) in 
24 pregnant patients with recrudescent multi-drug resist-
ant uncomplicated malaria. A noncompartmental and 
compartmental analysis was performed. For atovaquone, 
PG and CG, they found a lower (corrected) maximum 
concentration (Cmax) and total exposure (AUC) in preg-
nant women compared with healthy volunteers from 
the same population [78] and compared with Thai chil-
dren with malaria [79]. The terminal elimination half-life 
of atovaquone was significantly longer in the pregnant 
women. The non-compartmental analysis for PG showed 
40  % lower maximum concentrations (Cmax) and expo-
sure (AUC) in pregnant women with acute malaria than 
in non-pregnant healthy adults. The lower PG concentra-
tions were attributed in the population pharmacokinetic 
assessment to increased apparent volume of distribution 
and clearance rate.
Another study by McGready et al. [48] investigated the 
influences of pregnancy on biotransformation of PG to 
CG. They found similar PG plasma concentrations 6  h 
after administration of a single dose of PG (200 mg p.o.) 
in 45 women during pregnancy and the same 45 women 
at least two months post partum. Plasma concentrations 
(corrected for dose) of CG 6 h after administration of PG 
were significantly lower during pregnancy than post par-
tum (25.0 vs 37.4  ng/ml; p  <  0.01). The ratio of plasma 
and urine PG and CG concentrations increased signifi-
cantly in pregnancy. The urine concentration of PG and 
CG were significantly higher during pregnancy.
Na Bangchang et  al. [44] studied the pharmacokinet-
ics of atovaquone and PG in pregnant women from 
Thailand (n =  8) and Zambia (n =  18) treated with AP 
(1000/400  mg p.o. q.d. for 3  days) for uncomplicated 
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falciparum malaria. They found no significant differences 
in any of the pharmacokinetic parameters of atovaquone, 
PG or CG between patients from Thailand and Zambia. 
Atovaquone was slowly absorbed and slowly eliminated 
with considerable variation among individuals. The 
maximum concentration (Cmax) and exposure (AUC) of 
atovaquone found in this study were approximately half 
of those found in other studies in healthy volunteers and 
Thai children with malaria [79, 80]. No significant differ-
ences were seen in the pharmacokinetics of PG. Both the 
maximum concentration (Cmax) and exposure (AUC) of 
CG were considerably lower in this study compared to 
other studies [79–81].
Discussion
This systematic review synthesized and compiled data on 
ACT pharmacokinetics and dynamics during pregnancy, 
and the consequences thereof on treatment dose and 
regime. The previous systematic review on this subject 
was published in 2009 [29]. The present review encom-
passes 27 reports with a total of 829 pregnant and 377 
non-pregnant women [18, 19, 32–55]. The number of 
trials that were found are rather limited and dispropor-
tional low in view of to the large number of pregnant 
women with malaria infections worldwide. This has sev-
eral reasons, first of all, pregnant women are systemati-
cally excluded from clinical trials (because of the risk of 
the unborn child to be exposed to harmful effects). Fur-
thermore, there is a limited research funding available 
for trials, especially pharmacokinetic studies. Funding 
organizations prefer phase III or randomized clinical tri-
als over pharmacokinetic studies. The identified studies 
also differed in quality (see Additional file  3). However, 
in general, study quality was moderate to good, and the 
evidence is strong enough to draw conclusions regard-
ing pharmacokinetic changes that are exhibited in preg-
nant women. Although current WHO guidelines strongly 
recommend to treat malaria in the first trimester with 
quinine (combined with clindamycine), these will not be 
discussed in this review which is focussed on ACT.
Artemether, artesunate and dihydroartemisinin
Artemisinin-based compounds have been investigated 
in good quality studies. Two studies on the pharma-
cokinetic properties of artemether and its principle 
metabolite DHA suggest that the maximum concentra-
tion (Cmax) and exposure (AUC) of artemether and DHA 
following treatment with oral AL are lower in pregnant 
women than in non-pregnant patients. It also showed 
that there is no significant difference between the second 
and third trimester of pregnancy [36, 49]. However, since 
there has been no direct comparative trial, these results 
should be interpreted with caution. A larger sample size 
comparative trial should be conducted to statistically 
confirm or rule out any clinically important effect of 
pregnancy on pharmacokinetic parameters.
Although the outcome of the studies on the pharma-
cokinetic properties of AS seem conflicting, they provide 
substantial evidence that pregnancy induces clearance 
and thus leads to lower exposure to AS and DHA. 
While three studies found a higher DHA exposure [51] 
or no significant differences in DHA pharmacokinetics 
between the two groups [33, 41], other studies provided 
enough evidence to explain this apparent contradiction 
by the independent and opposite effect of malaria infec-
tion on pharmacokinetic properties [41, 46, 49, 59]. The 
higher bioavailability and exposure resulting from malar-
ial infection in thought to have masked the pregnancy 
related effects on pharmacokinetics. This conclusion is 
worrying as pregnant women might be at risk of under 
dosing, resulting in lower cure rates and a more rapid 
development of resistance to DHA, and urgently calls for 
reassessment of the treatment dose of artesunate. The 
exact mechanisms are unfortunately currently unknown. 
A dose optimization study will be necessary to find the 
ideal dose of artesunate-containing ACT in pregnancy in 
order to augment clinical efficacy and ensure safety.
Pharmacokinetic properties after administration of 
oral DHA were investigated in two studies. A non-com-
partmental analysis of the data of the first study showed 
a trend of lower exposure. However, the differences were 
only statistically significant after the first dose, possibly 
because of small sample sizes and high inter-individual 
variability. The compartmental analysis of the same data 
showed 38 % lower total exposure and significantly higher 
clearance rates and apparent volume of distribution. The 
second study reported no differences in pharmacokinetic 
properties between pregnant and non-pregnant women. 
Of interest, the first study included women with falcipa-
rum malaria, while the parasitaemic rate of the partici-
pants was very low in the second study. Further studies 
with larger sample sizes of the effect of pregnancy on 
DHA pharmacokinetics are recommended.
Lumefantrine
An important development in the past 5  years are that 
several controlled studies were published on lumefan-
trine. Studies investigating the pharmacokinetic proper-
ties of lumefantrine show a low day 7 concentration and 
large proportions of concentrations below values that are 
associated with high failure rates [18, 19, 35, 37, 49, 61]. 
One study also showed a significantly lower lumefan-
trine exposure in pregnant women [49], while another 
study showed significantly shorter Tmax and T1/2, but no 
statistically significant differences in lumefantrine expo-
sure [37]. Especially the lower day 7 concentrations are 
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reason for concern and ask for more extensive research 
and reconsideration of the drug dose. Future stud-
ies should investigate whether drug exposure improves 
with a standard six-dose regimen of lumefantrine given 
over 5 days compared to the standard regimen of 3 days. 
Important to note is that still much remains unknown 
regarding the variable absorption of lumefantrine (which 
is a lipophilic compound) in the digestive tract affect-
ing pharmacokinetic values. In the included trials in this 
review, the absorption of lumefantrine was maximized by 
providing fatty foods (e.g. milk). However, in daily clinical 
practice in endemic countries, it is completely unknown 
which percentage of (pregnant) women co-administer 
high-fat foods.
Amodiaquine
The reported studies with oral amodiaquine for the treat-
ment of vivax malaria in Thailand revealed no clinically 
relevant differences in pharmacokinetic parameters 
between pregnant and post-partum women. There was 
no significant difference between post-partum women 
with malaria and without malaria, making it unlikely that 
a disease effect masked possible differences. Therefore, 
no dosage adjustments are recommended.
Mefloquine
Two studies dating from 1990 and 1994 report signifi-
cantly lower maximum concentrations of mefloquine in 
pregnant women compared to healthy Brazilian volun-
teers [43, 64] and non-pregnant women [45]. In contrast 
to a recent study that showed similar values for Cmax in 
pregnant and non-pregnant women with falciparum 
malaria and a non-significant trend towards longer clear-
ance and higher exposure to mefloquine. In the first two 
studies, patients received one dose of oral AS in a low 
dose as prophylaxis [43] or in a higher dose as treatment 
for chloroquine-resistant falciparum malaria [45], while 
in the recent study a 3 days course of treatment of given 
[33]. These differences in drug regimes, besides other 
variables, might have an influence on the pharmacoki-
netic parameters. It was thought that altered plasma con-
centrations of mefloquine were caused by the increased 
volume of distribution. The results of the most recent 
trial [33] suggests that although the exposure was higher, 
the carboxymefloquine concentration was reduced (with 
simultaneous increase in V/F and removal of the metab-
olite). The reduced carboxylation might be partially 
responsible for the of the compound in pregnant women. 
Larger trials with comparative drug regimens, metabolite 
profiles and compartmental analysis and patient groups 
would thus be necessary to draw strong conclusions on 
the effect of pregnancy on the pharmacokinetic proper-
ties of mefloquine.
Sulfadoxine‑pyrimethamine
The reported studies with SP (used for IPTp) all show a 
significant lower exposure, higher clearance rates and 
shorter terminal half-life of sulfadoxine in pregnant 
women compared with post-partum women [42, 52, 54]. 
This suggests that higher doses of sulfadoxine would be 
beneficial for the efficacy of IPTp even when the parasites 
are fully susceptible to sulfa drug combinations.
No general conclusion can be drawn for the pyrimeth-
amine pharmacokinetics, since a study in Kenya showed 
no differences in pharmacokinetic parameters between 
pregnant and post-partum women [54], while a study 
in Papua New Guinea (PNG) reported significantly 
lower exposure and higher clearance rates [52]. A study 
in four African countries described significantly higher 
exposure and lower clearance rates in pregnant women. 
Possible explanations could be the different rates of para-
sitaemia between the studies (0–43  %) and the concur-
rent administration of chloroquine in the study in PNG. 
Further (observational or interventional) research will 
be necessary to assess the influence of pregnancy on the 
pharmacokinetic properties of pyrimethamine. However, 
with resistance hampering its use, the prospects for an 
extended PK evaluation of sulfa drug combinations used 
for IPTp appear to be limited [82]. The search for suitable 
alternative drug (combinations) for IPTp is ongoing [83].
Piperaquine
The reported studies suggest an influence of pregnancy 
on the pharmacokinetic properties of PQ. Four of the five 
studies show either an elevated exposure after the first 
dose [39, 55], a (significantly) higher Cmax and shorter 
terminal elimination half-lifes [34, 39, 53, 55]. However, 
none of the studies showed a significantly higher total 
exposure, probably limiting the clinical consequences of 
the influence of pregnancy. Thereby, one study reported 
a significantly lower exposure in the pregnant group, a 
shorter half-life and a higher apparent volume of distri-
bution. These discrepancies emphasize the need for fur-
ther research.
Atovaquone
The studies investigating atovaquone pharmacokinetics 
show a more than 50 % lower Cmax and total exposure in 
pregnant women with falciparum malaria compared to 
healthy volunteers [44, 50]. Although these results should 
be interpreted with caution due to small sample sizes, 
higher dosing of atovaquone ought to be considered.
Proguanil
The pharmacokinetic parameters of PG did not differ 
significantly in most studies, but the maximum con-
centration and terminal elimination half-life of the 
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active metabolite of PG, CG, were significantly lower 
and shorter in pregnant women. Also, the PG–CG-
ratio was significantly elevated in two studies, suggest-
ing an impaired conversion of PG to CG. Since CG is 
mainly responsible for the therapeutic effect of PG, this 
might compromise the efficacy; and as well, the dose of 
the PG portion in the AP combination may have to be 
re-considered.
Limitations
This systematic review is subject to several limitations. 
First, there is a considerable degree of heterogeneity in 
the outcomes and parameters that were reported in the 
articles. For example, time intervals for exposure differed 
significantly between the studies; which makes it more 
difficult to compare the outcomes of different studies. 
Also, different units and methods of measurement for 
the outcomes were used in different studies, complicating 
direct comparisons. Secondly, there was a large heteroge-
neity in the control groups. In some studies, the pregnant 
women acted as their own post-partum controls, with 
or without (symptomatic) malaria, while in other stud-
ies non-pregnant women or men were used, also with or 
without (symptomatic) malaria. In some studies no con-
trol group was available, so data were compared with lit-
erature values. There was a large heterogeneity between 
the pregnant women, especially regarding parasite den-
sity and gestational age estimates. Furthermore, the phar-
macokinetic sampling schemes differed among studies, 
which might have had an effect on the outcome param-
eters. Last, the relatively small sample sizes of all stud-
ies made it difficult to statistically confirm differences in 
pharmacokinetic properties. For these reasons, a meta-
analysis could unfortunately not be conducted.
Conclusion
This systematic review suggests that reassessment of 
the dose of some components of ACT is necessary to 
ensure the highest possible efficacy of malaria treat-
ment in pregnant women. Especially for artesunate, 
lumefantrine, sulfadoxine, atovaquone and proguanil 
evidence suggest that with current regimes, pregnant 
women are under-dosed. Evidence also indicates that 
the effect of pregnancy on amodiaquine and piperaquine 
is clinically not relevant and dose thus does not have to 
be changed. For artemether, dihydroartemisinin, lume-
fantrine, mefloquine and pyrimethamine more exten-
sive research with larger sample sizes is needed to draw 
strong conclusions on the effect of pregnancy on the 
pharmacokinetic parameters of these components of 
ACT. Novel approaches such as sampling methods using 
lower blood volumes and minimal preparation (e.g. dried 
blood spots, high sensitive drug assays), and population 
pharmacokinetics analysis that are able to investigate the 
effect of variables such as age, pregnancy, simultaneously 
administered drugs, can generate solid data that can 
inform treatment of malaria in pregnancy [84].
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